Sourcing · Regulatory · continued

Research-use-only labelling: what it means and what it does not — the long version posts 151–159

Sourcing › Regulatory EMA research use only compounding

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.

f.fontaineTL2 Moderator13 May 2025#151

t.abubakar, post #16: Approval versus licensing: a compound can be approved for a specific indication in one country and not approved at all in another. Tracking jurisdictional approval is tedious but necessary. Go to post

Labelling and intended use: a compound sold as "research-use-only" does not change its pharmacology if ingested. It changes the legal status of the sale. The labelling tells you the intended use, not the actual use people make of it.

20 likes in reply to #16 15mo

r.marsdenTL3Regular14 May 2025 · edited#152

Off-label use and medical practice: clinicians can prescribe approved medications off-label under some circumstances. That is different from research-use-only compounds, which are not approved for any human use.

0 likes 14mo

s.roosTL2 Moderator15 May 2025#153

post #152 is right about the mechanism and I think understates the practical bit.

Approval versus licensing: a compound can be approved for a specific indication in one country and not approved at all in another. Tracking jurisdictional approval is tedious but necessary.

0 likes 14mo

g.valckenaereTL3Regular17 May 2025#154

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.

5 likes 14mo

g.ekstromTL2 Moderator18 May 2025#155

ro.zielinski, post #32: I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient. Go to post

Why this category is maintained as documentation, not as recommendations: the goal is factual accuracy and sourcing, not endorsement of any specific regulatory position.

27 likes in reply to #32 14mo

BBramleyTL3Regular19 May 2025#156

z.vogel, post #67: post #66 answers the question as asked. The question underneath it is different. Approval versus licensing: a compound can be approved for a specific indication in one country and not approved at all in another. Tracking jurisdictional approval is tedious but necessary. Go to post

Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption. The label does not establish whether the molecule is safe, efficacious, or toxic.

0 likes in reply to #67 14mo

n.serranoTL2 Moderator20 May 2025#157

post #156 answers the question as asked. The question underneath it is different.

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

2 likes 14mo

LeitermanTL3Regular22 May 2025#158

On post #154 — agreed on the reasoning, with one qualification.

Import restrictions vary by compound and by jurisdiction: what is a controlled substance in one place is legal to purchase in another. What you can import for personal use depends on your country's rules, not on where it is sold.

8 likes 14mo

ni.stanescuTL2 Moderator23 May 2025 · edited#159

This follows post #156 rather than contradicting it.

Preclinical versus clinical: compounds with strong preclinical data can fail in clinical trials. Compounds with no human data are being used on theoretical grounds. The regulatory position reflects this asymmetry.

9 likes 14mo

Moved from Independent verification by bench_notes. Category placement is not obvious from outside and getting it wrong is expected. This topic will get better answers here. The move is recorded in the public log citing R7.

Suggested topics

Topic	Participants	Replies	Views	Activity
Enforcement priorities versus written rules — does this still hold? Sourcing › Regulatory EMA MHRA compounding FDA Solved Under review Enforcement priorities versus written rules — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Structured report rather than an opinion, following…	+36	40	37k	11mo
Second pass at: Import rules for personal quantities, by jurisdiction, dated Sourcing › Regulatory research use only personal import FDA MHRA Second pass at: Import rules for personal quantities, by jurisdiction, dated Writing it up because I had to work it out twice and would rather nobody else did. A logistics question, since the answers here are…		2	5k	11mo
Research-use-only labelling: what it means and what it does not Sourcing › Regulatory compounding research use only EMA FDA Posting this under the heading it deserves: Research-use-only labelling: what it means and what it does not Everything below is what sits behind that. I would like to talk about documentation quality as a…	+100	110	37k	5mo
Prescription requirements and telehealth models — a second dataset Sourcing › Regulatory compounding EMA MHRA personal import On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. A logistics question, since the answers here are usually better than…	+87	94	1.1k	21d
Enforcement priorities versus written rules Sourcing › Regulatory FDA personal import MHRA Enforcement priorities versus written rules — setting out what I have, and where I think it stops being reliable. I would like to talk about documentation quality as a signal, separately from product quality.…		2	62k	15mo

Related topics — sharing the tags EMA, research use only, compounding

Topic	Participants	Replies	Views	Activity
Pen wastage and its effect on real cost — the long version Access › Pricing formulary data table cost per milligram compounding Posting this under the heading it deserves: Pen wastage and its effect on real cost — the long version Everything below is what sits behind that. Documenting an access outcome, dated, because everything in…		2	34k	13mo
Second pass at: How to research a compound with no human data without deceiving yourself Compounds › Other compounds research use only custom synthesis needs a source mislabelling Second pass at: How to research a compound with no human data without deceiving yourself Writing it up because I had to work it out twice and would rather nobody else did. Comparing STEP 1 ( N Engl J Med ,…	+64	71	2.5k	13mo
EU-wide position versus national implementation Regional › European Union EMA personal import cost per milligram formulary Solved Under review EU-wide position versus national implementation Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because everything in this category…	+22	29	356	11mo
Coming back to: Payment method and the leverage it gives you, ranked Sourcing › Payments payments documentation quality research use only Payment method and the leverage it gives you, ranked — setting out what I have, and where I think it stops being reliable. Structured report rather than an opinion, following the format the maintainers asked…	+21	26	43k	2d
Second pass at: Hoarding and why it makes a shortage worse Access › Shortages FDA compounding shortage Second pass at: Hoarding and why it makes a shortage worse Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because everything in this…	+115	133	11k	21mo